Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage i lung adenocarcinoma Journal Article

   

Authors:	Kadota, K.; Nitadori, J. I.; Sarkaria, I. S.; Sima, C. S.; Jia, X.; Yoshizawa, A.; Rusch, V. W.; Travis, W. D.; Adusumilli, P. S.
Article Title:	Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage i lung adenocarcinoma
Abstract:	BACKGROUND: In the current study, the authors investigated whether thyroid transcription factor-1 (TTF-1) expression is correlated with the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and whether it stratifies patients with stage I lung adenocarcinoma with respect to disease recurrence. METHODS: Patients with stage I lung adenocarcinoma were classified according to the IASLC/ATS/ERS classification. Tissue microarrays were constructed and immunostaining for TTF-1 was performed. A total of 452 cases were available for analysis. Tumors were dichotomized based on the intensity of nuclear TTF-1 expression as negative (score of 0) or positive (score of 1-3). The cumulative incidence of recurrence (CIR) was used to estimate disease recurrence probabilities. RESULTS: TTF-1 expression was identified in 92% of patients, including 100% of patients with minimally invasive or lepidic-predominant adenocarcinoma, 94% of patients with acinar-predominant adenocarcinoma, 98% of patients with papillary-predominant adenocarcinoma, 93% of patients with micropapillary-predominant adenocarcinoma, 86% of patients with solid-predominant adenocarcinoma, 67% of patients with colloid-predominant adenocarcinoma, and 47% of patients with invasive mucinous carcinoma. The CIR for patients with negative TTF-1 expression (n = 34 patients; 5-year CIR, 40%) was significantly higher than that for patients with positive TTF-1 expression (n = 418 patients; 5-year CIR, 15%) (P <.001). Among the patients with intermediate-grade tumors, the CIR for patients with negative TTF-1 expression (n = 16 patients; 5-year CIR, 45%) was significantly higher than that for patients with positive TTF-1 expression (n = 313 patients; 5-year CIR, 14%) (P <.001). On multivariate analysis, negative TTF-1 expression was found to be significantly correlated with an increased risk of disease recurrence (hazards ratio, 2.55; P =.009). CONCLUSIONS: TTF-1 expression was found to be an independent predictor of disease recurrence, stratifying intermediate-grade tumors into 2 prognostic subsets, and it correlates with the IASLC/ATS/ERS classification. Cancer 2013. © 2012 American Cancer Society.
Keywords:	lung adenocarcinoma; histologic subtype; thyroid transcription factor-1; recurrence.
Journal Title:	Cancer
Volume:	119
Issue:	5
ISSN:	0008-543X
Publisher:	Wiley Blackwell
Date Published:	2013-03-01
Start Page:	931
End Page:	938
Language:	English
DOI:	10.1002/cncr.27863
PROVIDER:	scopus
PUBMED:	23096929
PMCID:	PMC3691693
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84874274525&partnerID=40&md5=8ea2cb335db6d61aa4c55b05582ea169
Notes:	--- - "Export Date: 1 April 2013" - "CODEN: CANCA" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/38858